Current therapy of systemic sclerosis (scleroderma).
Treatment of systemic sclerosis (scleroderma) presents a challenge to both the patient and the physician. Established approaches include long-term physiotherapy, disease-modifying agents such as D-penicillamine, and treatment of organ involvement. These efforts are often unsatisfactory since the results are poor. However, recent advances include treatment of Raynaud's phenomenon (plasmapheresis, stanozolol, and prostacyclin analogues), scleroderma renal crisis (angiotensin-converting enzyme inhibitors), and gastric hypomotility (cisapride). This article covers the current approaches to the disease-modifying therapy including those related to the function of collagen-producing fibroblasts, vascular alterations, and the cellular and humoral immune system, as well as treatment of involved organs.
Müller-Ladner
U
U
Medizinische Klinik und Poliklinik I, Universität Regensburg.
Benning
K
K
Lang
B
B
D058186:Acute Kidney Injury / Q000209:etiology; D004719:Endomyocardial Fibrosis / Q000209:etiology; D004730:Endothelium, Vascular / Q000187:drug effects; D005347:Fibroblasts / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology; D007167:Immunotherapy; D026741:Physical Therapy Modalities; D011006:Pneumatosis Cystoides Intestinalis / Q000209:etiology; D011658:Pulmonary Fibrosis / Q000209:etiology; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy / Q000628:therapy*